AMBI.XX News
Archived Headlines
- US IPO Recap: Activity remains robust with five pricings, five setting terms and four new filers 05/06/13
- Biotech Ambit Biosciences sets terms for $65 million IPO 05/02/13
- Weekly Recap: Filing updates could foreshadow a busy March for the US IPO market 02/25/13
- Ambit Biosciences refiles for a $58 million IPO 02/20/13
- Ambit Biosciences refiles for a $58 million IPO 02/20/13
See more
US IPO Recap: Marketo and Tableau soar, May calendar stays full
Exactly one year after Facebook priced its ill-fated IPO, two fast-growing technology companies, Marketo (MKTO) and Tableau (DATA), surged on their first days of trading. Marketo, a marketing software company, jumped 78% on Friday in the best first-day...read more
Ambit Biosciences prices IPO at $8
Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, raised $65 million by offering 8.1 million shares at $8. Ambit Biosciences plans to list on the NASDAQ under the symbol AMBI. Ambit Biosciences...read more
Ambit Biosciences revises terms for IPO, maintains $65 million deal size
Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, revised the terms for its upcoming IPO on Wednesday, but maintained the total proceeds. The San Diego, CA-based company now plans to raise $65 million...read more
7 US IPOs planned for the week of May 13
The following IPOs are expected to price this week: Ambit Biosciences (AMBI), which is developing small molecule therapeutics for the treatment of acute myeloid leukemia...read more